Lu-177 PSMA қуықасты безінің радиолиганда премиум бағдарламасы

• Лютеций-177-пен емдеу
• Операциядан кейінгі тексеріс
• Қан талдаулары
• Консультация дәрігері

• Трансфер әуежай-клиника-әуежай

LUTETIUM-177 PSMA RADIOLIGAND THERAPY PROGRAM

The Lutetium-177 (Lu-177) PSMA Radioligand Therapy Program is an advanced targeted treatment option for patients with metastatic, progressive, or treatment-resistant prostate cancer.

This program integrates molecular imaging assessment and radioligand therapy within a structured and carefully monitored treatment pathway.

Prior to therapy, a previously performed PSMA PET/CT scan is carefully reviewed and evaluated to confirm sufficient PSMA receptor expression and assess disease distribution. Treatment eligibility and the final therapy decision are determined based on this molecular imaging assessment, ensuring an individualized and precisely targeted approach.

The therapy utilizes Lutetium-177, a beta-emitting radioisotope attached to a PSMA-targeting molecule that selectively binds to prostate cancer cells. Once internalized, Lutetium-177 releases therapeutic radiation that damages tumor cell DNA, leading to controlled cancer cell destruction.

Because beta radiation has a moderate tissue penetration range, it allows effective treatment of metastatic lesions while maintaining an acceptable safety profile. This therapy is widely used for advanced prostate cancer patients who require systemic targeted treatment.

The program is conducted under the medical leadership of Assoc. Prof. Dr. Kezban Berberoğlu, Director of Nuclear Medicine, who brings more than 20 years of experience in nuclear medicine and advanced molecular imaging, supported by international academic training in the United States. All treatments are administered in a specialized nuclear medicine environment under strict safety and monitoring protocols.

The therapeutic compound is sourced through internationally regulated pharmaceutical supply channels, including certified medication suppliers in the United States, ensuring high manufacturing standards, quality control, and traceability.

The treatment package includes nuclear medicine consultation, comprehensive laboratory testing to assess kidney, liver, and hematologic function, administration of Lutetium-177 PSMA therapy, and structured post-treatment follow-up by a nuclear medicine specialist.

The recommended stay is approximately three days per treatment cycle, including arrival and departure, provided no significant side effects or unexpected medical events occur. If necessary, monitoring may be extended to ensure patient safety.

For patient convenience, cost-efficient partner hotels are available near the hospital, offering daily shuttle service between the hotel and the medical center to ensure smooth and organized logistics throughout the treatment process.

• Жеке дәрігер-координатор
• Сапарды ұйымдастыру — біздің серіктестерден төмендетілген бағамен билеттер мен қонақ үйлерді брондау
• Клиникаға бару барысында науқас мүдделерін қорғау